Literature DB >> 22533455

Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey.

S Zappa1, M McDaniel, J Marandola, G Allen.   

Abstract

Frequent evaluation of haemophilia treatment is necessary to improve patient care. The 2010 Practice Patterns Survey (PPS) investigated current trends in haemophilia treatment in the United States, as reported by nurses. The aim was to document practice patterns for haemophilia A and haemophilia B Survey questionnaires were sent to nurses at haemophilia treatment centres (HTCs) across the United States. Seventy-one of 126 HTCs (56%) responded to the survey. Factor dosage across treatment modalities ranged from 20 to 50 IU kg(-1) for severe haemophilia A. Dosage for severe haemophilia B was more variable (<40 to >100 IU kg(-1)). On-demand dosing regimens were inconsistent for haemophilia A and more so for haemophilia B. Rates of adherence to prescribed treatment were similar for both haemophilia types (∼80%). The main barrier to adherence was identified as inconvenience. More bleeding episodes occurred in adults (16.6 bleeding episodes per year) with severe haemophilia A than in younger patients (11.3 bleeding episodes per year) before switching patients to prophylaxis. For both haemophilia types, most patients who switched from prophylaxis to on-demand treatment were aged 13-24 years; these patients also had the lowest adherence (60-71%). More paediatric patients with severe haemophilia A and inhibitors (53%) received prophylactic bypassing therapy than their haemophilia B counterparts (38%). Adults with severe haemophilia A faced challenges in relation to co-morbidities and long-term care. This PPS provides insights into previously unexplored aspects of haemophilia care that will serve to increase awareness and promote discussion of current issues affecting haemophilia patient care.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22533455     DOI: 10.1111/j.1365-2516.2012.02770.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  14 in total

1.  Prophylaxis use among males with haemophilia B in the United States.

Authors:  M Ullman; Q C Zhang; S D Grosse; M Recht; J M Soucie
Journal:  Haemophilia       Date:  2017-08-06       Impact factor: 4.287

Review 2.  Management of Hemophilia in Older Patients.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

Review 3.  Current and emerging factor VIII replacement products for hemophilia A.

Authors:  Lorraine A Cafuir; Christine L Kempton
Journal:  Ther Adv Hematol       Date:  2017-08-26

4.  Validation of the Spanish Version of the VERITAS-PRN Scale to Assess Adherence to on Demand Regimens in Patients with Hemophilia.

Authors:  Ana Torres-Ortuño; Rubén Cuesta-Barriuso; Joaquín Nieto-Munuera; Álvaro Castiello-Munuera; José Antonio López-Pina
Journal:  Patient Prefer Adherence       Date:  2021-05-11       Impact factor: 2.711

5.  Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions.

Authors:  Shannon C Jackson; Ming Yang; Leonard Minuk; Michelle Sholzberg; Jean St-Louis; Alfonso Iorio; Robert Card; Man-Chiu Poon
Journal:  BMC Hematol       Date:  2015-02-14

Review 6.  Treatment adherence in hemophilia.

Authors:  Courtney D Thornburg; Natalie A Duncan
Journal:  Patient Prefer Adherence       Date:  2017-09-27       Impact factor: 2.711

7.  Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy.

Authors:  F Shafer; L Smith; N Vendetti; P Rendo; M Carr
Journal:  Haemophilia       Date:  2013-11-29       Impact factor: 4.287

8.  Utilization Patterns of Coagulation Factor Consumption for Patients with Hemophilia.

Authors:  Soo Ok Lee; Su-Yeon Yu
Journal:  J Korean Med Sci       Date:  2015-12-24       Impact factor: 2.153

9.  Patient and parent preferences for characteristics of prophylactic treatment in hemophilia.

Authors:  Roberto Furlan; Sangeeta Krishnan; Jeffrey Vietri
Journal:  Patient Prefer Adherence       Date:  2015-11-23       Impact factor: 2.711

10.  Understanding patient preferences and willingness to pay for hemophilia therapies.

Authors:  Shraddha S Chaugule; Joel W Hay; Guy Young
Journal:  Patient Prefer Adherence       Date:  2015-11-11       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.